Cardiovascular disease related to influenza infection and the protective role of influenza vaccination

Influenza infection is a well-established trigger of severe respiratory and cardiovascular complications, particularly in older adults, frail individuals, and patients with underlying cardiovascular disease. Seasonal peaks are consistently associated with excess hospitalizations and mortality. Epidemiological studies have shown sharp increases in acute cardiac events during and immediately after influenza infection, including a high-rate of acute coronary syndromes and heart failure. The cardiovascular impact of influenza is mediated by multiple mechanisms. Systemic inflammation, plaque destabilization, metabolic imbalance, endothelial dysfunction, and pro-thrombotic activation collectively contribute to acute coronary syndromes, myocarditis, arrhythmias, and acute or worsening heart failure. These complications generate a substantial clinical and socioeconomic burden, particularly in elderly and high-risk individuals. Despite the availability of effective and inexpensive vaccines, influenza vaccination remains underused in high-risk cardiovascular populations. Randomized trials and meta-analyses consistently support vaccination as a powerful preventive tool, associated with a 25-37% reduction in major adverse cardiovascular events and mortality, with benefits comparable to established cardioprotective therapies. Evidence is strongest in patients with coronary artery disease, ACS, diabetes, and in older adults, although results in heart failure populations remain more heterogeneous. Enhanced vaccines including adjuvanted, high-dose, and cell-based formulations offer superior protection in elderly and immunocompromised individuals and are increasingly recommended by national and international health authorities. Given the robust evidence linking influenza to cardiovascular events and the proven protective role of vaccination, systematic implementation of tailored influenza immunization strategies in patients with CVD is essential to optimize preventive care.

Authors

Institutions

Publication Details

Journal
International Journal of Cardiology
Published
2026-01-13
DOI
https://doi.org/10.1016/j.ijcard.2026.134178
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cardiovascular disease related to influenza infection and the protective role of influenza vaccination

R Siliquini, Massimo Volpe, Giulio Nati, Giovanni Gabutti
International Journal of Cardiology
Influenza Virus Research Studies
article

Cardiovascular disease related to influenza infection and the protective role of influenza vaccination

R Siliquini, Massimo Volpe, Giulio Nati, Giovanni Gabutti
article en

Abstract

Influenza infection is a well-established trigger of severe respiratory and cardiovascular complications, particularly in older adults, frail individuals, and patients with underlying cardiovascular disease. Seasonal peaks are consistently associated with excess hospitalizations and mortality. Epidemiological studies have shown sharp increases in acute cardiac events during and immediately after influenza infection, including a high-rate of acute coronary syndromes and heart failure. The cardiovascular impact of influenza is mediated by multiple mechanisms. Systemic inflammation, plaque destabilization, metabolic imbalance, endothelial dysfunction, and pro-thrombotic activation collectively contribute to acute coronary syndromes, myocarditis, arrhythmias, and acute or worsening heart failure. These complications generate a substantial clinical and socioeconomic burden, particularly in elderly and high-risk individuals. Despite the availability of effective and inexpensive vaccines, influenza vaccination remains underused in high-risk cardiovascular populations. Randomized trials and meta-analyses consistently support vaccination as a powerful preventive tool, associated with a 25-37% reduction in major adverse cardiovascular events and mortality, with benefits comparable to established cardioprotective therapies. Evidence is strongest in patients with coronary artery disease, ACS, diabetes, and in older adults, although results in heart failure populations remain more heterogeneous. Enhanced vaccines including adjuvanted, high-dose, and cell-based formulations offer superior protection in elderly and immunocompromised individuals and are increasingly recommended by national and international health authorities. Given the robust evidence linking influenza to cardiovascular events and the proven protective role of vaccination, systematic implementation of tailored influenza immunization strategies in patients with CVD is essential to optimize preventive care.

International Journal of CardiologyVol. 448
University of Ferrara (IT), ASL Roma (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Department of Public Health (US), Azienda Sanitaria Locale Roma 3 (IT), University of Florence (IT), Sapienza University of Rome (IT), Union des Industries Ferroviaires Européennes (BE)
Good health and well-being
Openalex Percentile: Top 89%
Influenza Virus Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.